Abstract
Amonafide, one of a series of benz[de]-isoquinoline-1,3-dione compounds, is now entering phase II clinical trials in this country. We tested amonafide, exposed continuously for 5 days, at four different concentrations against 56 primary human tumors in vitro. The drug concentration range used was based on amonafide's inhibitory activity against human bone marrow cells. The antitumor activity of 5-fluorouracil, mitomycin C, cisplatin, and etoposide against tumors from this panel of 56 was compared with that of amonafide at in vitro concentrations equitoxic against human bone marrow cells. Amonafide was active against only 12% of tumors compared with standard agents, which were active against more than 40% of tumors in the human bone marrow inhibitory range. Our data suggested that amonafide is less likely to be clinically active against human solid tumors than the standard agents.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Brana MF, Castellano JM, Roldan CM, Santos A, Vazquez D, Jimenez A: Synthesis and mode(s) of action of a new series of imide derivatives of 3-nitro-1,8-naphthalic acid. Cancer Chemother Pharmacol 4:61–66, 1980
Brana MF, Sanz AM: Synthesis and cytostatic activity of benz(de)isoquinoline-1,3-diones. Structure-activity relationships. Eur J Med Chem 16:207–212, 1981
Garca-Gancedo AG, Gil-Fernandez C, Vilas P, Perez S, Paez E, Rodriguez F, Brana MF, Roldan CM. Imide derivatives of 3-nitro-1,8-naphthalic acid: Their inhibitory activity against DNA viruses. Arch Virol 74:157–165, 1982
Leiby JM, Staubus AE, Malspeis L, Grever MR: Benzisoquinolinedione: A clinical phase I study. Proc Am Assoc Cancer Res 27: 249, 1986 (abstr)
Legha S, Tenney D, Lu K, Raber M, Newman R, Krakoff I: Phase I study of benzisoquinolinedione (BIDA), Nafidamide (NSC-308847). Proc Am Assoc Cancer Res 27:171, 1986 (abstr)
Waring MJ, Gonzales A, Jimenez A, Vazquez D: Intercalative binding to DNA of antitumor drugs derived from 3-nitro-1,8 naphthalic acid. Nucleic Acids Res 7:217–229, 1979
Andersson BS, Beran M, Bakic M, Silberman LE, Newman RA, Zwelling LA: In vitro toxicity and DNA cleaving capacity of Benzisoquinolinedione (Nafidamide; NSC 308847) in human leukemia. Cancer Res 47:1040–1044, 1987
Baker F, Spitzer G, Ajani J, Brock W, Lukeman J, Pathak S, Tomasovic B, Thielvoldt D, Williams M, Vines C, Tofilon P. Successful primary monolayer culturing of human tumor cells using cell-adhesive matrix and supplemented medium: drug and radiation sensitivity measurements. Cancer Res 46:1263–1274, 1986
Ajani JA, Baker FL, Spitzer G, Kelly A, Brock WA, Tomasovic B, Singletary SE, McMurtrey M, Plager C. Comparison between the clinical response and in vitro drug sensitivity of primary human tumors in the adhesive tumor cell culture system. J Clin Oncol 5:1912–1921, 1987
Brock WA, Baker FL, Peters LJ, Spitzer G, Bock S, Williams M. Radiosensitivity of human tumor cells in primary culture. Proc Natl Acad Sci USA, 1987 (in press)
Ajani JA, Spitzer G, Tomasovic B, Drewinko B, Hug V, Dicke K: In vitro cytotoxicity patterns of standard and investigational agents on human bone marrow granulocyte-macrophage progenitors cells. Br J Cancer 54:607–613, 1986
Fan D, Ajani JA, Baker FL, Tomasovic B, Brock WA, Spitzer G: Comparison of antitumor activity of standard and investigational drugs at equivalent granulocyte-macrophage colony-forming cell inhibitory concentrations in the adhesive tumor-cell culture system: An in vitro method of screening new drugs. Eur J Cancer Clin Oncol 1987 23:1469–1476, 1987
Hug B, Haynes M, Rashid R, Spitzer G, Blumenschein G, Hortobagyi G: Improved culture conditions for clonogenic growth of primary human breast tumors. Br J Cancer 50:207–213, 1984
Singltary SE, Baker FL, Spitzer G, Tucker S, Tomasovic B, Brock WA, Ajani JA, Kelly AM: Biologic effect of epidermal growth factor on the in vitro growth of human tumors. Cancer Res 47:403–406, 1987
Marsoni S, Hoth D, Simon R, Leyland-Jones B, De Rosa M, Wittes RE: Clinical drug development: An analysis of Phase II trials, 1970–1985. Cancer Treat Rep 71:71–80, 1987
Boyd M, Schoemaker R, Alley M, Scudiero N, Monks A, McLemore T, Gorelik E, Fine D, Mayo J, Chabner B: New NCI disease-oriented drug screening program. Invest New Drugs 5:78, 1987 (abstr)
Corbett TH, Valeriote FA, Baker LH: Is the P388 murine tumor no longer adequate as a drug discovery model? Invest New Drugs 5:3–30, 1987
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ajani, J.A., Baker, F.L. & Spitzer, G. In vitro activity of amonafide against primary human tumors compared with the activity of standard agents. Invest New Drugs 6, 79–85 (1988). https://doi.org/10.1007/BF00195364
Issue Date:
DOI: https://doi.org/10.1007/BF00195364